BiotechTube

rilzabrutinib + Glucocorticoids

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immunoglobulin G4 Related Disease

Conditions

Immunoglobulin G4 Related Disease

Trial Timeline

Aug 22, 2020 → Oct 15, 2024

NCT ID
NCT04520451

About rilzabrutinib + Glucocorticoids

rilzabrutinib + Glucocorticoids is a phase 2 stage product being developed by Sanofi for Immunoglobulin G4 Related Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04520451. Target conditions include Immunoglobulin G4 Related Disease.

What happened to similar drugs?

0 of 4 similar drugs in Immunoglobulin G4 Related Disease were approved

Approved (0) Terminated (0) Active (4)
🔄iptacopanNovartisPhase 3
🔄Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
🔄Felzartamab + PlaceboBiogenPhase 3
🔄sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04520451Phase 2Completed

Competing Products

11 competing products in Immunoglobulin G4 Related Disease

See all competitors
ProductCompanyStageHype Score
ABBV-383 (Etentamig)AbbViePhase 1/2
39
zigakibartNovartisPhase 2
42
iptacopanNovartisPhase 3
47
CCX168AmgenPhase 2
35
InebilizumabAmgenPhase 2
42
Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
47
FelzartamabBiogenPhase 2
32
Felzartamab + PlaceboBiogenPhase 3
44
SparsentanTravere TherapeuticsPhase 2
29
SparsentanTravere TherapeuticsPhase 2
33
sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3
38